NO311027B1 - Alkylaminobenzotiazol og -benzoksazolderivater - Google Patents
Alkylaminobenzotiazol og -benzoksazolderivater Download PDFInfo
- Publication number
- NO311027B1 NO311027B1 NO19985227A NO985227A NO311027B1 NO 311027 B1 NO311027 B1 NO 311027B1 NO 19985227 A NO19985227 A NO 19985227A NO 985227 A NO985227 A NO 985227A NO 311027 B1 NO311027 B1 NO 311027B1
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compound
- compounds
- alkyl
- dopamine
- Prior art date
Links
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical class C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 129
- 239000000203 mixture Substances 0.000 claims description 60
- 239000002904 solvent Substances 0.000 claims description 41
- 102000003962 Dopamine D4 receptors Human genes 0.000 claims description 37
- 108090000357 Dopamine D4 receptors Proteins 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 31
- 239000002253 acid Substances 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000000460 chlorine Substances 0.000 claims description 19
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 150000002431 hydrogen Chemical class 0.000 claims description 13
- 239000012442 inert solvent Substances 0.000 claims description 13
- 230000002285 radioactive effect Effects 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- 230000003042 antagnostic effect Effects 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000012458 free base Substances 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- 150000001204 N-oxides Chemical class 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000003384 imaging method Methods 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 4
- 239000012620 biological material Substances 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000163 radioactive labelling Methods 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 229910052722 tritium Inorganic materials 0.000 claims description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- GJLZNEQGOKEFTN-UHFFFAOYSA-N n-[2-(4-phenylpiperazin-1-yl)ethyl]-1,3-benzothiazol-2-amine Chemical compound N=1C2=CC=CC=C2SC=1NCCN(CC1)CCN1C1=CC=CC=C1 GJLZNEQGOKEFTN-UHFFFAOYSA-N 0.000 claims description 2
- GJSYHSRNGCLVHN-UHFFFAOYSA-N n-[2-[4-(3,4-dichlorophenyl)piperazin-1-yl]ethyl]-1,3-benzothiazol-2-amine Chemical compound C1=C(Cl)C(Cl)=CC=C1N1CCN(CCNC=2SC3=CC=CC=C3N=2)CC1 GJSYHSRNGCLVHN-UHFFFAOYSA-N 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims 1
- 238000000844 transformation Methods 0.000 claims 1
- 239000000543 intermediate Substances 0.000 description 49
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 38
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 29
- 239000000243 solution Substances 0.000 description 26
- -1 for example Proteins 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000003480 eluent Substances 0.000 description 16
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 230000027455 binding Effects 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 208000028017 Psychotic disease Diseases 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 5
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 5
- 102000015554 Dopamine receptor Human genes 0.000 description 5
- 108050004812 Dopamine receptor Proteins 0.000 description 5
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 5
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- PXFJLKKZSWWVRX-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)piperazine Chemical compound C1=C(Cl)C(Cl)=CC=C1N1CCNCC1 PXFJLKKZSWWVRX-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000000164 antipsychotic agent Substances 0.000 description 4
- 229940005529 antipsychotics Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 230000000561 anti-psychotic effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 150000004885 piperazines Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
- BSQLQMLFTHJVKS-UHFFFAOYSA-N 2-chloro-1,3-benzothiazole Chemical compound C1=CC=C2SC(Cl)=NC2=C1 BSQLQMLFTHJVKS-UHFFFAOYSA-N 0.000 description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 2
- 229940093475 2-ethoxyethanol Drugs 0.000 description 2
- VIQFVCWBQRWTSO-UHFFFAOYSA-N 3-[4-(3,4-dichlorophenyl)piperazin-1-yl]propan-1-amine Chemical compound C1CN(CCCN)CCN1C1=CC=C(Cl)C(Cl)=C1 VIQFVCWBQRWTSO-UHFFFAOYSA-N 0.000 description 2
- RKFLCDRQGFRNHE-UHFFFAOYSA-N 4-[4-(3,4-dichlorophenyl)piperazin-1-yl]butan-1-amine Chemical compound C1CN(CCCCN)CCN1C1=CC=C(Cl)C(Cl)=C1 RKFLCDRQGFRNHE-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000000543 Histamine Receptors Human genes 0.000 description 2
- 108010002059 Histamine Receptors Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 102000034337 acetylcholine receptors Human genes 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000002932 anti-schizophrenic effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 239000006274 endogenous ligand Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- QDTDFSFRIDFTCF-UHFFFAOYSA-N n-phenyl-1,3-benzothiazol-2-amine Chemical compound N=1C2=CC=CC=C2SC=1NC1=CC=CC=C1 QDTDFSFRIDFTCF-UHFFFAOYSA-N 0.000 description 2
- 230000000955 neuroendocrine Effects 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- XXQBEVHPUKOQEO-UHFFFAOYSA-N potassium superoxide Chemical compound [K+].[K+].[O-][O-] XXQBEVHPUKOQEO-UHFFFAOYSA-N 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000010956 selective crystallization Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LGIYMTHBRYKVSV-WLHGVMLRSA-N (e)-but-2-enedioic acid;n-[5-[4-(3,4-dichlorophenyl)piperazin-1-yl]pentyl]-1,3-benzothiazol-2-amine Chemical compound OC(=O)\C=C\C(O)=O.C1=C(Cl)C(Cl)=CC=C1N1CCN(CCCCCNC=2SC3=CC=CC=C3N=2)CC1 LGIYMTHBRYKVSV-WLHGVMLRSA-N 0.000 description 1
- BZTNECSSZCOPQS-UHFFFAOYSA-N 1-(2-chloroethyl)-4-(3,4-dichlorophenyl)piperazine Chemical compound C1CN(CCCl)CCN1C1=CC=C(Cl)C(Cl)=C1 BZTNECSSZCOPQS-UHFFFAOYSA-N 0.000 description 1
- PJHPFAFEJNBIDC-UHFFFAOYSA-N 1-(4-bromophenyl)piperazine Chemical compound C1=CC(Br)=CC=C1N1CCNCC1 PJHPFAFEJNBIDC-UHFFFAOYSA-N 0.000 description 1
- NCMNOXVMCMQZAE-UHFFFAOYSA-N 1-[2-[4-(3,4-dichlorophenyl)piperazin-1-yl]ethyl]-3-(4-methylphenyl)thiourea Chemical compound C1=CC(C)=CC=C1NC(=S)NCCN1CCN(C=2C=C(Cl)C(Cl)=CC=2)CC1 NCMNOXVMCMQZAE-UHFFFAOYSA-N 0.000 description 1
- NIDSRGCVYOEDFW-UHFFFAOYSA-N 1-bromo-4-chlorobutane Chemical compound ClCCCCBr NIDSRGCVYOEDFW-UHFFFAOYSA-N 0.000 description 1
- QKAOOWJWWKWWOZ-UHFFFAOYSA-N 1-isothiocyanato-2-methoxybenzene Chemical compound COC1=CC=CC=C1N=C=S QKAOOWJWWKWWOZ-UHFFFAOYSA-N 0.000 description 1
- VRPQCVLBOZOYCG-UHFFFAOYSA-N 1-isothiocyanato-4-methoxybenzene Chemical compound COC1=CC=C(N=C=S)C=C1 VRPQCVLBOZOYCG-UHFFFAOYSA-N 0.000 description 1
- ABQKHKWXTUVKGF-UHFFFAOYSA-N 1-isothiocyanato-4-methylbenzene Chemical compound CC1=CC=C(N=C=S)C=C1 ABQKHKWXTUVKGF-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- FRQMJZZUNJTQCS-UHFFFAOYSA-N 2-[4-(3,4-dichlorophenyl)piperazin-1-yl]ethanamine Chemical compound C1CN(CCN)CCN1C1=CC=C(Cl)C(Cl)=C1 FRQMJZZUNJTQCS-UHFFFAOYSA-N 0.000 description 1
- UHIQVPRCDRTUKV-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)piperazin-1-yl]ethanamine Chemical compound C1CN(CCN)CCN1C1=CC=C(Cl)C=C1 UHIQVPRCDRTUKV-UHFFFAOYSA-N 0.000 description 1
- FVUFTABOJFRHSU-UHFFFAOYSA-N 2-chloro-6-methoxy-1,3-benzothiazole Chemical compound COC1=CC=C2N=C(Cl)SC2=C1 FVUFTABOJFRHSU-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- PGNZHTWRCXOGQQ-UHFFFAOYSA-N 3-(4-naphthalen-1-ylpiperazin-1-yl)propan-1-amine Chemical compound C1CN(CCCN)CCN1C1=CC=CC2=CC=CC=C12 PGNZHTWRCXOGQQ-UHFFFAOYSA-N 0.000 description 1
- KNLCRNWJXCLJHQ-UHFFFAOYSA-N 3-(4-phenylpiperazin-1-yl)propan-1-amine Chemical compound C1CN(CCCN)CCN1C1=CC=CC=C1 KNLCRNWJXCLJHQ-UHFFFAOYSA-N 0.000 description 1
- VBIRKPRVXHHCPJ-UHFFFAOYSA-N 3-[4-(3,4-dichlorophenyl)piperazin-1-yl]propanenitrile Chemical compound C1=C(Cl)C(Cl)=CC=C1N1CCN(CCC#N)CC1 VBIRKPRVXHHCPJ-UHFFFAOYSA-N 0.000 description 1
- BTWFACODYSMZPB-UHFFFAOYSA-N 3-[4-(4-bromophenyl)piperazin-1-yl]propan-1-amine Chemical compound C1CN(CCCN)CCN1C1=CC=C(Br)C=C1 BTWFACODYSMZPB-UHFFFAOYSA-N 0.000 description 1
- BZXMNIDJAOLPGX-UHFFFAOYSA-N 3-[4-(4-nitrophenyl)piperazin-1-yl]propan-1-amine Chemical compound C1CN(CCCN)CCN1C1=CC=C([N+]([O-])=O)C=C1 BZXMNIDJAOLPGX-UHFFFAOYSA-N 0.000 description 1
- GJEAKTQHQWHRSU-UHFFFAOYSA-N 4-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]-6-fluoro-1,3-benzothiazol-2-amine Chemical compound Nc1nc2c(CCN3CCN(CC3)c3ccc(Cl)cc3)cc(F)cc2s1 GJEAKTQHQWHRSU-UHFFFAOYSA-N 0.000 description 1
- ODMVPIBDMHLJIT-UHFFFAOYSA-N 4-[4-(2,4-dimethylphenyl)piperazin-1-yl]butan-1-amine Chemical compound CC1=CC(C)=CC=C1N1CCN(CCCCN)CC1 ODMVPIBDMHLJIT-UHFFFAOYSA-N 0.000 description 1
- FJPMHRVWHIDPMQ-UHFFFAOYSA-N 4-[4-(4-bromophenyl)piperazin-1-yl]butan-1-amine Chemical compound C1CN(CCCCN)CCN1C1=CC=C(Br)C=C1 FJPMHRVWHIDPMQ-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- YJWYECKPBYKZSI-UHFFFAOYSA-N 5-(4-naphthalen-1-ylpiperazin-1-yl)pentan-1-amine Chemical compound C1CN(CCCCCN)CCN1C1=CC=CC2=CC=CC=C12 YJWYECKPBYKZSI-UHFFFAOYSA-N 0.000 description 1
- IUJAXFLKTQXMHJ-UHFFFAOYSA-N 5-(methylamino)pentan-1-ol Chemical compound CNCCCCCO IUJAXFLKTQXMHJ-UHFFFAOYSA-N 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- ZTAWOYNDMPXVCF-UHFFFAOYSA-N 5-[4-(2,4-dimethylphenyl)piperazin-1-yl]pentan-1-amine Chemical compound CC1=CC(C)=CC=C1N1CCN(CCCCCN)CC1 ZTAWOYNDMPXVCF-UHFFFAOYSA-N 0.000 description 1
- XZVPQKGPUSWLOS-UHFFFAOYSA-N 5-[4-(3,4-dichlorophenyl)piperazin-1-yl]pentan-1-amine Chemical compound C1CN(CCCCCN)CCN1C1=CC=C(Cl)C(Cl)=C1 XZVPQKGPUSWLOS-UHFFFAOYSA-N 0.000 description 1
- KHBBGXOQJPBHHI-UHFFFAOYSA-N 5-[4-(3,4-dichlorophenyl)piperazin-1-yl]pentanenitrile Chemical compound C1=C(Cl)C(Cl)=CC=C1N1CCN(CCCCC#N)CC1 KHBBGXOQJPBHHI-UHFFFAOYSA-N 0.000 description 1
- JSAWFGSXRPCFSW-UHFFFAOYSA-N 5-chloropentanenitrile Chemical compound ClCCCCC#N JSAWFGSXRPCFSW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- UYDMJSVBZLNEPI-WLHGVMLRSA-N C(\C=C\C(=O)O)(=O)O.ClC1=CC=C(C=C1)N1CCN(CC1)CCNC=1SC2=C(N1)C=CC=C2 Chemical compound C(\C=C\C(=O)O)(=O)O.ClC1=CC=C(C=C1)N1CCN(CC1)CCNC=1SC2=C(N1)C=CC=C2 UYDMJSVBZLNEPI-WLHGVMLRSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 1
- FZRRNEIUVJSPEA-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.c1c(Cl)c(Cl)ccc1N1CCN(CCN(c2nc3ccccc3s2)c2ccccc2)CC1 Chemical compound OC(=O)\C=C\C(O)=O.c1c(Cl)c(Cl)ccc1N1CCN(CCN(c2nc3ccccc3s2)c2ccccc2)CC1 FZRRNEIUVJSPEA-WLHGVMLRSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000014993 Pituitary disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 244000171263 Ribes grossularia Species 0.000 description 1
- 235000002357 Ribes grossularia Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000004974 alkaline earth metal peroxides Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003326 anti-histaminergic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 229940075894 denatured ethanol Drugs 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 108010037444 diisopropylglutathione ester Proteins 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- QHSHDVYEJKLXLB-UHFFFAOYSA-N ethyl n-(2-chloroethyl)carbamate Chemical compound CCOC(=O)NCCCl QHSHDVYEJKLXLB-UHFFFAOYSA-N 0.000 description 1
- WMJGQJCTFSOAQM-UHFFFAOYSA-N ethyl n-[2-[4-(4-bromophenyl)piperazin-1-yl]ethyl]carbamate Chemical compound C1CN(CCNC(=O)OCC)CCN1C1=CC=C(Br)C=C1 WMJGQJCTFSOAQM-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001660 hyperkinetic effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- RDTKXZZISRTZAR-UHFFFAOYSA-N n-(4-chlorobutyl)-n-phenyl-1,3-benzothiazol-2-amine Chemical compound N=1C2=CC=CC=C2SC=1N(CCCCCl)C1=CC=CC=C1 RDTKXZZISRTZAR-UHFFFAOYSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- NUJVXJQWONGBHO-UHFFFAOYSA-N n-(5-chloropentyl)-n-phenyl-1,3-benzothiazol-2-amine Chemical compound N=1C2=CC=CC=C2SC=1N(CCCCCCl)C1=CC=CC=C1 NUJVXJQWONGBHO-UHFFFAOYSA-N 0.000 description 1
- AEXVFHAEENHHAU-UHFFFAOYSA-N n-[2-[4-(3,4-dichlorophenyl)piperazin-1-yl]ethyl]-6-methyl-1,3-benzothiazol-2-amine Chemical compound S1C2=CC(C)=CC=C2N=C1NCCN(CC1)CCN1C1=CC=C(Cl)C(Cl)=C1 AEXVFHAEENHHAU-UHFFFAOYSA-N 0.000 description 1
- FIKWONMUWBVBJJ-UHFFFAOYSA-N n-[2-[4-(3,4-dichlorophenyl)piperazin-1-yl]ethyl]-n-methyl-1,3-benzothiazol-2-amine Chemical compound N=1C2=CC=CC=C2SC=1N(C)CCN(CC1)CCN1C1=CC=C(Cl)C(Cl)=C1 FIKWONMUWBVBJJ-UHFFFAOYSA-N 0.000 description 1
- KSNPSEKRGHRSPW-UHFFFAOYSA-N n-[2-[4-(4-bromophenyl)piperazin-1-yl]ethyl]-1,3-benzothiazol-2-amine Chemical compound C1=CC(Br)=CC=C1N1CCN(CCNC=2SC3=CC=CC=C3N=2)CC1 KSNPSEKRGHRSPW-UHFFFAOYSA-N 0.000 description 1
- FHWYOFCYSFHXDS-UHFFFAOYSA-N n-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]-1,3-benzothiazol-2-amine Chemical compound C1=CC(Cl)=CC=C1N1CCN(CCNC=2SC3=CC=CC=C3N=2)CC1 FHWYOFCYSFHXDS-UHFFFAOYSA-N 0.000 description 1
- SQQQAJILYVEUFG-UHFFFAOYSA-N n-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]-7-methoxy-1,3-benzothiazol-2-amine;hydrochloride Chemical compound Cl.S1C=2C(OC)=CC=CC=2N=C1NCCN(CC1)CCN1C1=CC=C(Cl)C=C1 SQQQAJILYVEUFG-UHFFFAOYSA-N 0.000 description 1
- NHYYKVOAPGFKHL-UHFFFAOYSA-N n-[3-(4-phenylpiperazin-1-yl)propyl]-1,3-benzothiazol-2-amine Chemical compound N=1C2=CC=CC=C2SC=1NCCCN(CC1)CCN1C1=CC=CC=C1 NHYYKVOAPGFKHL-UHFFFAOYSA-N 0.000 description 1
- AJYSDQBKCRYQNF-UHFFFAOYSA-N n-[3-[4-(3,4-dichlorophenyl)piperazin-1-yl]propyl]-6-methoxy-1,3-benzothiazol-2-amine;dihydrochloride Chemical compound Cl.Cl.S1C2=CC(OC)=CC=C2N=C1NCCCN(CC1)CCN1C1=CC=C(Cl)C(Cl)=C1 AJYSDQBKCRYQNF-UHFFFAOYSA-N 0.000 description 1
- ODJJJYLWJQCPDH-UHFFFAOYSA-N n-[3-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]propyl]-1,3-benzothiazol-2-amine Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCCNC=3SC4=CC=CC=C4N=3)CC2)=C1 ODJJJYLWJQCPDH-UHFFFAOYSA-N 0.000 description 1
- LUABFORHKKFGEL-UHFFFAOYSA-N n-[4-[4-(3,4-dichlorophenyl)piperazin-1-yl]butyl]-6-methyl-1,3-benzothiazol-2-amine Chemical compound S1C2=CC(C)=CC=C2N=C1NCCCCN(CC1)CCN1C1=CC=C(Cl)C(Cl)=C1 LUABFORHKKFGEL-UHFFFAOYSA-N 0.000 description 1
- HVQAGCYLLHLDAE-UHFFFAOYSA-N n-[4-[4-(4-methoxyphenyl)piperazin-1-yl]butyl]-1,3-benzothiazol-2-amine Chemical compound C1=CC(OC)=CC=C1N1CCN(CCCCNC=2SC3=CC=CC=C3N=2)CC1 HVQAGCYLLHLDAE-UHFFFAOYSA-N 0.000 description 1
- AZCNTPSPOFJQJA-UHFFFAOYSA-N n-[5-[4-(3,4-dichlorophenyl)piperazin-1-yl]pentyl]-1,3-benzothiazol-2-amine Chemical compound C1=C(Cl)C(Cl)=CC=C1N1CCN(CCCCCNC=2SC3=CC=CC=C3N=2)CC1 AZCNTPSPOFJQJA-UHFFFAOYSA-N 0.000 description 1
- OTISWVDIFYXZDC-WLHGVMLRSA-N n-benzyl-n-[5-[4-(3,4-dichlorophenyl)piperazin-1-yl]pentyl]-1,3-benzothiazol-2-amine;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=C(Cl)C(Cl)=CC=C1N1CCN(CCCCCN(CC=2C=CC=CC=2)C=2SC3=CC=CC=C3N=2)CC1 OTISWVDIFYXZDC-WLHGVMLRSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 229940054010 other antipsychotics in atc Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 238000003567 signal transduction assay Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 239000004544 spot-on Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96201282 | 1996-05-10 | ||
| PCT/EP1997/002505 WO1997043271A1 (en) | 1996-05-10 | 1997-05-02 | Alkylaminobenzothiazole and -benzoxazole derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO985227D0 NO985227D0 (no) | 1998-11-09 |
| NO985227L NO985227L (no) | 1999-01-11 |
| NO311027B1 true NO311027B1 (no) | 2001-10-01 |
Family
ID=8223970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19985227A NO311027B1 (no) | 1996-05-10 | 1998-11-09 | Alkylaminobenzotiazol og -benzoksazolderivater |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US6103725A (hu) |
| EP (2) | EP1325917B1 (hu) |
| JP (1) | JP3237759B2 (hu) |
| KR (1) | KR100330699B1 (hu) |
| CN (1) | CN1074766C (hu) |
| AR (1) | AR007079A1 (hu) |
| AT (2) | ATE277917T1 (hu) |
| AU (1) | AU710175B2 (hu) |
| BG (1) | BG64097B1 (hu) |
| BR (1) | BR9709065A (hu) |
| CA (1) | CA2253453C (hu) |
| CZ (1) | CZ295639B6 (hu) |
| DE (2) | DE69730962T2 (hu) |
| EA (1) | EA001360B1 (hu) |
| EE (1) | EE03563B1 (hu) |
| ES (2) | ES2279923T3 (hu) |
| HK (2) | HK1018457A1 (hu) |
| HU (1) | HUP9902993A3 (hu) |
| ID (1) | ID16889A (hu) |
| IL (1) | IL126968A0 (hu) |
| MY (1) | MY117852A (hu) |
| NO (1) | NO311027B1 (hu) |
| NZ (1) | NZ332309A (hu) |
| PL (1) | PL190721B1 (hu) |
| SK (1) | SK282919B6 (hu) |
| TR (1) | TR199802253T2 (hu) |
| TW (1) | TW593290B (hu) |
| WO (1) | WO1997043271A1 (hu) |
| ZA (1) | ZA974053B (hu) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1293804B1 (it) | 1997-08-01 | 1999-03-10 | Recordati Chem Pharm | Diarilalchilpiperazine attive sulle basse vie urinarie |
| US6281216B1 (en) * | 1998-02-09 | 2001-08-28 | Duphar International Research B.V. | 2-aminoquinoline derivatives having d4-agonistic activity |
| EP0982030A3 (en) * | 1998-08-17 | 2000-05-10 | Pfizer Products Inc. | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands |
| CN1325397A (zh) * | 1998-09-30 | 2001-12-05 | 纽罗根公司 | 2－哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体 |
| US6284759B1 (en) * | 1998-09-30 | 2001-09-04 | Neurogen Corporation | 2-piperazinoalkylaminobenzo-azole derivatives: dopamine receptor subtype specific ligands |
| US6107313A (en) * | 1998-10-02 | 2000-08-22 | Combichem, Inc. | Dopamine receptor antagonists |
| AU5569800A (en) * | 1999-06-30 | 2001-01-31 | Santen Pharmaceutical Co. Ltd. | Brain sigma-1 receptor-binding ligand |
| DE60128211T2 (de) | 2000-03-31 | 2008-01-10 | Ortho-Mcneil Pharmaceutical, Inc. | Phenyl-substituierte imidazopyridine |
| AU2001251083A1 (en) * | 2000-03-31 | 2001-10-15 | Ortho-Mcneil Pharmaceutical, Inc. | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists |
| GB0203299D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel compounds |
| KR20050033662A (ko) * | 2002-09-06 | 2005-04-12 | 얀센 파마슈티카 엔.브이. | 헤테로사이클릭 화합물 |
| JP5070038B2 (ja) * | 2004-02-24 | 2012-11-07 | ザ ジェネラル ホスピタル コーポレーション | 触媒性放射性フッ素化 |
| US8257680B1 (en) | 2004-02-24 | 2012-09-04 | The General Hospital Corporation | Catalytic radiofluorination |
| US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
| FR2877005A1 (fr) | 2004-10-22 | 2006-04-28 | Bioprojet Soc Civ Ile | Nouveaux derives d'arylpiperazine |
| US7731940B2 (en) | 2006-01-25 | 2010-06-08 | The Regents Of The University Of California | Compositions and methods related to serotonin 5-HT1A receptors |
| CA2978149C (en) | 2008-03-21 | 2019-02-12 | The General Hospital Corporation | Inositol derivatives for the detection and treatment of alzheimer's disease and related disorders |
| WO2018039512A1 (en) * | 2016-08-26 | 2018-03-01 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| PT109740B (pt) | 2016-11-14 | 2020-07-30 | Hovione Farmaciencia Sa | Processo para a preparação de brometo de umeclidínio |
| KR20210091865A (ko) * | 2020-01-14 | 2021-07-23 | 서울대학교산학협력단 | 혈관생성 저해 효과를 가지는 n-페닐벤조티아졸-2-아민 화합물 및 그를 포함하는 약제학적 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0187162B1 (en) * | 1984-05-22 | 1989-11-02 | Sumitomo Chemical Company, Limited | Novel radioactive iodospiroperidol and process for its preparation |
| CA1302403C (en) * | 1987-04-08 | 1992-06-02 | Steven C. Quay | Amyloidosis and alzheimer's disease diagnostic assay and reagents therefor |
| US4929618A (en) * | 1988-03-25 | 1990-05-29 | Ube Industries, Ltd. | Piperdine and piperazine derivatives, and antihistaminic pharmaceutical compositions containing the same |
| FR2656609B1 (fr) * | 1989-12-28 | 1992-03-27 | Synthelabo | Derives de 2-aminopyrimidine-4-carboxamide, leur preparation et leur application en therapeutique. |
| US5731438A (en) * | 1996-08-01 | 1998-03-24 | Isis Pharmaceuticals, Inc. | N-(aminoalkyl)-and/or N-(amidoalkyl)-dinitrogen heterocycles |
-
1997
- 1997-05-01 TW TW086105767A patent/TW593290B/zh not_active IP Right Cessation
- 1997-05-02 CZ CZ19983553A patent/CZ295639B6/cs not_active IP Right Cessation
- 1997-05-02 TR TR1998/02253T patent/TR199802253T2/xx unknown
- 1997-05-02 AT AT97923913T patent/ATE277917T1/de not_active IP Right Cessation
- 1997-05-02 EE EE9800378A patent/EE03563B1/xx not_active IP Right Cessation
- 1997-05-02 HU HU9902993A patent/HUP9902993A3/hu unknown
- 1997-05-02 PL PL97329849A patent/PL190721B1/pl not_active IP Right Cessation
- 1997-05-02 SK SK1532-98A patent/SK282919B6/sk not_active IP Right Cessation
- 1997-05-02 DE DE69730962T patent/DE69730962T2/de not_active Expired - Lifetime
- 1997-05-02 CA CA002253453A patent/CA2253453C/en not_active Expired - Fee Related
- 1997-05-02 NZ NZ332309A patent/NZ332309A/xx unknown
- 1997-05-02 EA EA199801000A patent/EA001360B1/ru not_active IP Right Cessation
- 1997-05-02 JP JP54053597A patent/JP3237759B2/ja not_active Expired - Lifetime
- 1997-05-02 DE DE69737217T patent/DE69737217T2/de not_active Expired - Lifetime
- 1997-05-02 ES ES03075959T patent/ES2279923T3/es not_active Expired - Lifetime
- 1997-05-02 CN CN97194515A patent/CN1074766C/zh not_active Expired - Lifetime
- 1997-05-02 IL IL12696897A patent/IL126968A0/xx not_active IP Right Cessation
- 1997-05-02 US US09/180,369 patent/US6103725A/en not_active Expired - Lifetime
- 1997-05-02 AU AU29560/97A patent/AU710175B2/en not_active Ceased
- 1997-05-02 WO PCT/EP1997/002505 patent/WO1997043271A1/en active IP Right Grant
- 1997-05-02 EP EP03075959A patent/EP1325917B1/en not_active Expired - Lifetime
- 1997-05-02 AT AT03075959T patent/ATE350373T1/de not_active IP Right Cessation
- 1997-05-02 ES ES97923913T patent/ES2230605T3/es not_active Expired - Lifetime
- 1997-05-02 EP EP97923913A patent/EP0912533B1/en not_active Expired - Lifetime
- 1997-05-02 KR KR1019980707914A patent/KR100330699B1/ko not_active IP Right Cessation
- 1997-05-02 BR BR9709065A patent/BR9709065A/pt not_active IP Right Cessation
- 1997-05-07 MY MYPI97002022A patent/MY117852A/en unknown
- 1997-05-09 ID IDP971546A patent/ID16889A/id unknown
- 1997-05-09 AR ARP970101955A patent/AR007079A1/es active IP Right Grant
- 1997-05-09 ZA ZA974053A patent/ZA974053B/xx unknown
-
1998
- 1998-10-07 BG BG102819A patent/BG64097B1/bg unknown
- 1998-11-09 NO NO19985227A patent/NO311027B1/no unknown
-
1999
- 1999-08-16 HK HK99103545A patent/HK1018457A1/xx not_active IP Right Cessation
- 1999-08-16 HK HK03109371A patent/HK1057044A1/xx not_active IP Right Cessation
-
2000
- 2000-06-27 US US09/604,427 patent/US6224849B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO311027B1 (no) | Alkylaminobenzotiazol og -benzoksazolderivater | |
| EP0912552B1 (en) | 2,4-diaminopyrimidine derivates as dopamine d4 receptor antagonists | |
| CN100402032C (zh) | 用作毒蕈碱激动剂的四氢喹啉类似物 | |
| CZ2000726A3 (cs) | Tetrahydro-gama-karboliny a způsob jejich přípravy | |
| JP2008509962A (ja) | ５−ｈｔ７受容体アンタゴニスト | |
| US5919784A (en) | Heterocyclic aminomethyl compounds | |
| JP2008509961A (ja) | ５−ｈｔ７受容体アンタゴニスト | |
| JP4590102B2 (ja) | 医薬としての三環性δ３−ピペリジン類 | |
| JP4580555B2 (ja) | α２アンタゴニストとしてのベンゾチエノ［３，２−ｃ］ピリジン類 | |
| AU708344C (en) | 2,4-diaminopyrimidine derivates as dopamine D4 receptor antagonists | |
| CN118647615A (zh) | 用于治疗精神障碍的苯并异噻唑和苯并异噁唑化合物 | |
| JP2586552B2 (ja) | ピペラジン化合物 | |
| CN110869375A (zh) | 2-氧代-1-咪唑烷基咪唑并噻二唑衍生物 | |
| MXPA01003514A (en) | BENZOTHIENO[3,2-c]PYRIDINES AS&agr;2 | |
| MXPA01003512A (en) | TRICYCLIC&Dgr;3-PIPERIDINES AS PHARMACEUTICALS |